Assignee
PHASEBIO PHARMACEUTICALS INC
US·10 granted patents·16 pending applications·25 citations·filing 2007–2022
Top patents by PatentIndex Score
26 records- 0192US11136309B2Metalloenzyme inhibitor compoundsPHASEBIO PHARMACEUTICALS INC·Filed 2020·Granted Oct 5, 2021·3 cites·4 claims
- 0290US11040034B2Metalloenzyme inhibitor compoundsPHASEBIO PHARMACEUTICALS INC·Filed 2018·Granted Jun 22, 2021·3 cites·4 claims
- 0386US9919032B2Method for administering a sustained release formulationPHASEBIO PHARMACEUTICALS INC·Filed 2016·Granted Mar 20, 2018·3 cites·20 claims
- 0485US9700598B2Modified vasoactive intestinal peptidesPHASEBIO PHARMACEUTICALS INC·Filed 2015·Granted Jul 11, 2017·5 cites·15 claims
- 0584US7709227B2Multimeric ELP fusion constructsPHASEBIO PHARMACEUTICALS INC·Filed 2007·Granted May 4, 2010·9 cites·11 claims
- 0679US10688156B2Methods and compositions for treating muscle disease and disordersPHASEBIO PHARMACEUTICALS INC·Filed 2016·Granted Jun 23, 2020·2 cites·15 claims
- 0773US2022288170A1Methods and compositions for treating muscle disease and disordersPHASEBIO PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 0869US11266719B2Methods and compositions for treating muscle disease and disordersPHASEBIO PHARMACEUTICALS INC·Filed 2020·Granted Mar 8, 2022·0 cites·15 claims
- 0964US2022023390A1Methods and compositions for treating cystic fibrosisPHASEBIO PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1064US2013178416A1Fusion peptide therapeutic compositionsPHASEBIO PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 1164US2020353091A1Elp fusion proteins for controlled and sustained releasePHASEBIO PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 1260US10722590B2ELP fusion proteins for controlled and sustained releasePHASEBIO PHARMACEUTICALS INC·Filed 2015·Granted Jul 28, 2020·0 cites·28 claims
- 1360US2023192895A1Pharmacokinetic & pharmacodynamic model for determining effective dose of anti-ticagrelor antibodyPHASEBIO PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1459US11052132B2Methods and compositions for treating cystic fibrosisPHASEBIO PHARMACEUTICALS INC·Filed 2015·Granted Jul 6, 2021·0 cites·16 claims
- 1558US2015290328A1Formulations of active agents for sustained releasePHASEBIO PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 1657US2018008677A1Modified vasoactive intestinal peptidesPHASEBIO PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 1755US2023173030A1Vasoactive intestinal peptide fusion proteins for the treatment of covid-19PHASEBIO PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1853US10940182B2Use of modified vasoactive intestinal peptides in the treatment of hypertensionPHASEBIO PHARMACEUTICALS INC·Filed 2016·Granted Mar 9, 2021·0 cites·19 claims
- 1949US2014171370A1Formulations of active agents for sustained releasePHASEBIO PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 2048US2022289812A1Elp fusion proteins comprising parathyroid hormone for controlled and sustained releasePHASEBIO PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 2146US2021347915A1Methods of reversing ticagrelor activityPHASEBIO PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 2245US2014364362A1Therapeutic agents comprising insulin amino acid sequencesPHASEBIO PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 2344US2015111816A1Methods and treatment with glp-1 receptor agonistsPHASEBIO PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 2443US2019218274A1Elp fusion proteins for controlled and sustained releasePHASEBIO PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 2542US2013150291A1Therapeutic agents comprising insulin amino acid sequencesPHASEBIO PHARMACEUTICALS INC·Filed 2012·Application pending·0 cites
- 2639US2015361154A1Therapeutic agents, compositions, and methods for glycemic controlPHASEBIO PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when PHASEBIO PHARMACEUTICALS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →